Romlusevimab

DB16494InvestigationalProtein Based Therapies

Romlusevimab (BRII-198) was under investigation in clinical trials (NCT04479644 and NCT04691180) to treat COVID-19, focusing on its safety, tolerability, and pharmacokinetics.

Mechanism: BRII-196 is a human monoclonal antibody extracted from a recovered patient of COVID-19. It binds to an epitope on the Spike protein of SARS-CoV-2 that is different from the one that is bound by BRII-196, thus having an additive to synergistic effect when used in combination with BRII-196. It is currently being investigated against COVID-19.
Curator reviewed
Also known as: IMMUNOGLOBULIN G1-LAMBDA2, ANTI-(SEVERE ACUTE RESPIRATORYSYNDROME CORONAVIRUS 2 (SARS-COV-2) SPIKE (S) GLYCOPROTEIN,RECEPTOR BINDING DOMAIN (RBD)), HOMO SAPIENS MONOCLONALANTIBODY
Code names: BRII-198

Resolves to

Compound

UNIISM01RRU9KKCAS2509447-08-7

Targets

P0DTC2S

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Romlusevimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account